Accelerate Brain Cancer Cure's investment enables Agios, a Boston based biopharmaceutical company, to explore whether the mutated IDH1 gene has an enzyme activity consistent with a cancer-causing gene, or oncogene. Press Release
Genentech's Avastin was granted accelerated approval by the Food and Drug Administration (FDA) to treat patients with recurrent brain tumors, representing the first treatment to be approved in a decade. Read more
Accelerate Brain Cancer Cure (ABC2) believes that a nimble, focused and aggressive entrepreneurial model will increase the number of therapies discovered and then enable those therapies to be more rapidly driven into the clinic. We provide researchers with the pivotal support they need to make critical breakthroughs. We fund novel translational research aimed at finding the fastest possible route to a cure.
ABC2 invests in each stage of the therapeutic development pipeline. Our Pre-Clincial Screening Program breaks down barriers to entry, our Research Grants focuses on novel therapies, and our collaborations with industry allows us to bring the most promising treatments to patients quickly.
ABC2 understands that fighting brain cancer is a team effort. We seek to bring together those who care about advancing therapies for patients. Our mission is straightforward: to accelerate the development of treatments that will lead to a cure for brain cancer. In this effort your support plays a key role in getting us there.